Swiss multicenter study evaluating the efficacy, feasibility and safety of peginterferon-alfa-2a and ribavirin in patients with chronic hepatitis C in official opiate substitution programs

Digestion

Volumn 78, Issue 2-3, 2008, Pages 123-130

  Fried, Ronald ^a,i   Monnat, Martine ^b   Seidenberg, André ^c   Oppliger, Robert ^c   Schmid, Patrick ^d   Herold, Markus ^e   Isler, Marc ^e   Broers, Barbara ^f   Kölliker, Christoph ^e   Schönbucher, Peter ^g   Frei, Markus ^g   Huber, Milo ^h  

^a Gastroenterology and Hepatology   (Switzerland)

^b Centre Saint Martin   (Switzerland)

^c General Medicine   (Switzerland)

^d Division of Infectious Diseases   (Switzerland)

^e Die Arbeitsgemeinschaft fur risikoarmen Umgang mit Drogen   (Switzerland)

^f UNIVERSITY HOSPITAL   (Switzerland)

^g General Medicine   (Switzerland)

^h UNIVERSITY HOSPITAL ZURICH   (Switzerland)

ⁱ NONE   (Switzerland)

Author keywords

Antiviral therapy; Hepatitis C; Opiate substitution

Indexed keywords

ANTIDEPRESSANT AGENT; BENZODIAZEPIN 2 ONE DERIVATIVE; BUPRENORPHINE; DIAMORPHINE; METHADONE; OPIATE; PEGINTERFERON ALPHA2A; RIBAVIRIN;

ABDOMINAL PAIN; ADULT; ALOPECIA; ANEMIA; ANOREXIA; ANTIVIRAL THERAPY; ARTICLE; CLINICAL TRIAL; CONCURRENT INFECTION; DEPRESSION; DRUG DEPENDENCE; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; DRUG SUBSTITUTION; DRY SKIN; DYSPEPSIA; EYE DISEASE; FATIGUE; FEASIBILITY STUDY; FEMALE; FLU LIKE SYNDROME; GENOTYPE; GRANULOCYTOPENIA; HEADACHE; HEPATITIS C; HUMAN; IMMUNOASSAY; INJECTION SITE ERYTHEMA; INSOMNIA; INTRAVENOUS DRUG ABUSE; IRRITABILITY; LABORATORY DIAGNOSIS; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYALGIA; NAUSEA; NEUTROPENIA; PATIENT COMPLIANCE; PRIORITY JOURNAL; PRURITUS; SCREENING; SIDE EFFECT; THORAX DISEASE; THROMBOCYTOPENIA; TREATMENT RESPONSE; VIREMIA; VOMITING;

ADULT; AGED; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; DRUG USERS; FEASIBILITY STUDIES; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RIBAVIRIN; TREATMENT OUTCOME;

EID: 56349096483     PISSN: 00122823     EISSN: None     Source Type: Journal    
DOI: 10.1159/000173733     Document Type: Article

References (39)

1. Marcellin P, Asselah T, Boyer N: Fibrosis and disease progression in hepatitis C. Hepatology 2002;36(5 suppl 1):S47-S56.
2. Broers B, Junet C, Bourquin M, Deglon JJ, Perrin L, Hirschel B: Prevalence and incidence rate of HIV, hepatitis B and C among drug users on methadone maintenance treatment in Geneva between 1988 and 1995. AIDS 1998;12:2059-2066.
3. Edlin BR: Prevention and treatment of hepatitis C in injection drug users. Hepatology 2002;36(5 suppl 1):S210-S219.
4. Steffen T, Gutzwiller F: Hepatitis B and C in intravenous drug abusers in Switzerland. Schweiz Rundsch Med Prax 1999;88:1937-1944.
5. Bruggmann P, Seidenberg A, Meili D, Kesseli B, Huber M: Hepatitis-C- und HIV-Prävalenz sowie antiretrovirale Therapie in einem niederschwelligen Opiatsubstitutions-programm - Eine Querschnittsanalyse. Suchttherapie 2005;6:78-82.
6. Hagan H, Latka MH, Campbell JV, Golub ET, Garfein RS, Thomas DA, Kapadia F, Strathdee SA; Study to Reduce Intravenous Exposures Project Team: Eligibility for treatment of hepatitis C virus infection among young injection drug users in 3 US cities. Clin Infect Dis 2006;42:669-672.
7. Roy K, Hay G, Andragetti R, Taylor A, Goldberg D, Wiessing L: Monitoring hepatitis C virus infection among injecting drug users in the European Union: a review of the literature. Epidemiol Infect 2002;129:577-585.
8. Edlin BR, Carden MR: Injection drug users: the overlooked core of the hepatitis C epidemic. Clin Infect Dis 2006;42:673-676.
9. Garfein RS, Doherty MC, Monterroso ER, Thomas DL, Nelson KE, Vlahov D: Prevalence and incidence of hepatitis C virus infection among young adult injection drug users. J Acquir Immune Defic Syndr Hum Retrovirol 1998;18(suppl 1):S11-S19.
10. Hagan H, Thiede H, Weiss NS, Hopkins SG, Duchin JS, Alexander ER: Sharing of drug preparation equipment as a risk factor for hepatitis C. Am J Publ Health 2001;91:42-46.
11. Hahn JA, Page-Shafer K, Lum PJ, Bourgois P, Stein E, Evans JL, Busch MP, Tobler LH, Phelps B, Moss AR: Hepatitis C virus sero-conversion among young injection drug users: relationships and risks. J Infect Dis 2002;186:1558-1564.
12. Judd A, Hickman M, Jones S, McDonald T, Parry JV, Stimson GV, Hall AJ: Incidence of hepatitis C virus and HIV among new injecting drug users in London: prospective cohort study. BMJ 2005;330:24-25.
13. Grob PJ, Negro F, Renner EL: Hepatitis C-Virus-Infektion. Praxis 2000;89:1587-1604.
14. Zeuzem S, Feinman SV, Rasenack J, Heathcote EJ, Lai MY, Gane E, O'Grady J, Reichen J, Diago M, Lin A, Hoffman J, Brunda MJ: Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000;343:1666-1672.
15. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK: Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-965.
16. Lauer GM, Walker BD: Hepatitis C virus infection. N Engl J Med 2001;345:41-52.
17. Chander G, Sulkowski MS, Jenckes MW, Torbenson MS, Herlong HF, Bass EB, Gebo KA: Treatment of chronic hepatitis C: a systematic review. Hepatology 2002;36(5 suppl 1):S135-S144.
18. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, Häussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J: Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-982.
19. EASL International Consensus Conference on Hepatitis C. Paris, 26-27 February 1999. Consensus statement. J Hepatol 1999;31(suppl 1):3-8.
20. Keeffe EB, Hollinger FB: Therapy of hepatitis C: consensus interferon trials. Consensus Interferon Study Group. Hepatology 1997;26(3 suppl 1):101S-107S.
21. Davis GL: Treatment of chronic hepatitis C. BMJ 2001;323:1141-1142.
22. Edlin BR, Seal KH, Lorvick J, Kral AH, Ciccarone DH, Moore LD, Lo B: Is it justifiable to withhold treatment for hepatitis C from illicit-drug users? N Engl J Med 2001;345:211-215.
23. Backmund M, Meyer K, Von Zielonka M, Eichenlaub D: Treatment of hepatitis C infection in injection drug users. Hepatology 2001;34:188-193.
24. National Institutes of Health Consensus Development Conference: Management of Hepatitis C: 2002. Hepatology 2002;36(5 suppl 1):S3-S20.
25. Schaefer M, Heinz A, Backmund M: Treatment of chronic hepatitis C in patients with drug dependence: time to change the rules? Addiction 2004;99:1167-1175.
26. Broers B, Helbling B, François A, Schmid P, Chuard C, Hadengue A, Negro F; Swiss Association for the Study of the Liver (SASL 18): Barriers to interferon-alpha therapy are higher in intravenous drug users than in other patients with acute hepatitis C. J Hepatol 2005;42:323-328.
27. Backmund M, Reimer J, Meyer K, Gerlach JT, Zachoval R: Hepatitis C virus infection and injection drug users: prevention, risk factors, and treatment. Clin Infect Dis 2005;40(suppl 5):S330-S335.
28. Sylvestre DL: Treating hepatitis C in methadone maintenance patients: an interim analysis. Drug Alcohol Depend 2002;67:117-123.
29. Sylvestre DL, Litwin AH, Clements BJ, Gourevitch MN: The impact of barriers to hepatitis C virus treatment in recovering heroin users maintained on methadone. J Subst Abuse Treat 2005;29:159-165.
30. Huber M, Weber R, Oppliger R, Vernazza P, Schmid P, Schönbucher P, Bertisch B, Meili D, Renner EL: Interferon alpha-2a plus ribavirin 1,000/1,200 mg versus interferon alpha-2a plus ribavirin 600 mg for chronic hepatitis C infection in patients on opiate maintenance treatment: an open-label randomized multicenter trial. Infection 2005;33:25-29.
31. Rehm J, Gschwend P, Steffen T, Gutzwiller F, Dobler-Mikola A, Uchtenhagen A: Feasibility, safety, and efficacy of injectable heroin prescription for refractory opioid addicts: a follow-up study. Lancet 2001;358:1417-1423.
32. Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, Lok AS: A simple non-invasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003;38:518-526.
33. Davis GL: Monitoring of viral levels during therapy of hepatitis C. Hepatology 2002;36:S145-S151.
34. Mauss S, Berger F, Goelz J, Jacob B, Schmutz G: A prospective controlled study of interferon-based therapy of chronic hepatitis C in patients on methadone maintenance. Hepatology 2004;40:120-124.
35. Guadagnino V, Trotta MP, Montesano F, Babudieri S, Caroleo B, Armignacco O, Carioti J, Maio G, Monarca R, Antinori A; Nocchiero Study Group: Effectiveness of a multi-disciplinary standardized management model in the treatment of chronic hepatitis C in drug addicts engaged in detoxification programmes. Addiction 2007;102:423-431.
36. Robaeys G, Van Vlierberghe H, Mathei C, Van Ranst M, Bruckers L, Buntinx F: Similar compliance and effect of treatment in chronic hepatitis C resulting from intravenous drug use in comparison with other infection causes. Eur J Gastroenterol Hepatol 2006;18:159-166.
37. Broers B, Morabia A, Hirschel B: A cohort study of drug users' compliance with zidovudine treatment. Arch Intern Med 1994;154:1121-1127.
38. Shehab TM, Orrego M, Chunduri R, Lok AS: Identification and management of hepatitis C patients in primary care clinics. Am J Gastroenterol 2003;98:639-644.
39. Huber M, Schmid P, Vernazza P, Meili D: Gründe für die ausbleibende Hepatitis C Behandlung bei Drogenabhängigen in Opiatsubstitution. Suchtther Suppl 2002;3:S27-S30.